natgillin/translations-raw huggingface dataset:
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present. 
Zaradi sočasne uporabe rifampicina in repaglinida lahko torej pride do potrebe po prilagajanju odmerka repaglinida, ki mora temeljiti na skrbnem nadziranju vrednosti glukoze v krvi, tako ob uvedbi zdravljenja z rifampicinom (akutna inhibicija) kot ob nadaljnjevanju (mešana inhibicija in indukcija) ter ukinitvi zdravljenja (samo indukcija) in še približno do dva tedna po ukinitvi rifampicina, ko indukcijski učinek rifampicina izzveni.
The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in concentrating. 
Opozorilni znaki hipe se lahko pojavijo nenadoma in lahko vključujejo: hladno znojenje, hladno in bledo kožo, glavobol, hitro bitje srca, občutek slabosti, hudo lakoto, prehodne spremembe vida, zaspanost, nenavadno utrujenost in šibkost, živčnost ali tresenje, občutek tesnobe, občutek zmedenosti in težave s koncentracijo.
Contact a doctor immediately. 
Nemudoma se posvetujte s svojim zdravnikom.
Short-term administration of repaglinide may be sufficient during periods of transient loss of control in Type 2 diabetic patients usually controlled well on diet. 
Kratkotrajna uporaba repaglinida lahko zadošča v obdobjih prehodne izgube urejenosti sladkorne bolezni tipa 2 pri bolnikih, pri katerih je bolezen ponavadi dobro urejena z dieto.
What Enyglid is and what it is used for 
Kaj je zdravilo Enyglid in za kaj ga uporabljamo
The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people (see If you get a hypo in section 2). 
Hipoglikemija je najpogostejši neželeni učinek, ki se lahko pojavi pri največ 1 od 10 bolnikov (glejte odstavek V primeru pojava hipe v poglavju 2).
Blister pack (OPA/Alu/PVC-Alu): 30, 60, 90, 120, 180, 270 and 360 tablets in the box. 
Pretisni omot (OPA/Al/PVC-Al): 30, 60, 90, 120, 180, 270 in 360 tablet v škatli.
The blood glucose-lowering effect of oral hypoglycaemic medicinal products decreases in many patients over time. 
Učinkovitost zniževanja glukoze v krvi s peroralnimi antidiabetiki se pri številnih bolnikih sčasoma zmanjša.
The most frequently reported adverse reactions are changes in blood glucose levels, i.e. hypoglycaemia. 
Neželeni učinki, o katerih so poročali najpogosteje, so spremembe vrednosti glukoze v krvi, kot je hipoglikemija.
A number of medicinal products are known to influence repaglinide metabolism, possible interactions should therefore be taken into account by the physician: 
Na presnovo repaglinida lahko vplivajo številna zdravila, zato mora zdravnik upoštevati možne interakcije.
Alcohol can change the ability of Enyglid to reduce the blood sugar. 
Alkohol lahko spremeni sposobnost zdravila Enyglid, da zniža vrednost krvnega sladkorja.
As hypoglycaemia in this study was avoided through increased calorie intake, a relative overdose may result in an exaggerated glucose lowering effect with development of hypoglycaemic symptoms (dizziness, sweating, tremor, headache etc.). 
Ker so se hipoglikemiji v tej študiji izognili z večjim kaloričnim vnosom; lahko relativno preveliko odmerjanje povzroči čezmerno znižanje glukoze in pojav simptomov hipoglikemije (omotica, znojenje, tremor, glavobol, ipd.).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. 
Bolnikom je treba svetovati, da morajo upoštevati ustrezne varnostne ukrepe, da med upravljanjem vozila ne bi prišlo do hipoglikemije.
Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data) 
Pogostnost je opredeljena kot: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Enyglid with alcohol 
Zdravila Enyglid skupaj z alkoholom
When repaglinide was given 24 hours after the last rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone). 
Če so osebe repaglinid prejele 24 ur po zadnjem odmerku rifampicina, so opazili 80 % zmanjšanje vrednosti AUC repaglinida (učinek samo indukcije).
What you need to know before you take Enyglid). 
Kaj morate vedeti, preden boste vzeli zdravilo Enyglid).
Repaglinide pharmacokinetics are characterised by a mean absolute bioavailability of 63% (CV 11%). 
Za farmakokinetiko repaglinida je značilna 63-% povprečna absolutna biološka uporabnost (koeficient variabilnosti je 11 %).
Symptoms such as swelling, difficulty in breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction. 
Simptomi, kot so otekanje, težave z dihanjem, pospešeno bitje srca, omotica in znojenje, so lahko znaki anafilaktične reakcije.
Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, drugi antidiabetiki razen insulinov, oznaka ATC: A10BX02.
The amount of Enyglid, food or exercise may need to be adjusted. 
Morda bo treba prilagoditi odmerek zdravila Enyglid, količino zaužite hrane ali stopnjo telesne dejavnosti.
The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction), see sections 4.8 and 5.1. 
Uporabo repaglinida lahko spremlja večja pojavnost akutnega koronarnega sindroma (npr. miokardni infarkt), glejte poglavji 4.8 in 5.1.
If your blood sugar is low or you feel a hypo coming on eat glucose tablets or a high sugar snack or drink, then rest. 
Če se vam krvni sladkor preveč zniža ali začutite pojav hipe, zaužijte tablete glukoze ali prigrizek z veliko sladkorja in nato počivajte.
Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction. 
Repaglinid se sme predpisati le, če se slaba urejenost glikemije in simptomi sladkorne bolezni nadaljujejo kljub ustrezni dieti, telesni dejavnosti in zmanjšanju telesne mase.
Doses are usually taken within 15 minutes of the meal, but the time may vary from immediately preceding the meal to as long as 30 minutes before the meal. 
Odmerek se običajno vzame v 15 minutah pred obrokom, vendar pa se lahko ta čas giblje v razponu od tik pred obrokom do 30 minut pred njim.
Less than 1% of repaglinide is recovered in faeces. 
Z blatom se izloči manj kot 1 % repaglinida.
After reaching a maximum, the plasma level decreases rapidly. 
Potem ko doseže največjo vrednost, se plazemska koncentracija hitro zmanjša.
Repaglinide acts through a distinct binding site with a short action on the β-cells. 
Repaglinid deluje prek posebnega vezavnega mesta s kratkim delovanjem na celice .
Other medicines and Enyglid 
Druga zdravila in zdravilo Enyglid
The concomitant use of gemfibrozil and repaglinide is contraindicated (see section 4.3). 
Sočasna uporaba gemfibrozila in repaglinida je tako kontraindicirana (glejte poglavje 4.3).
There is no reason to suspect cross-allergenicity with sulphonylurea due to the difference in chemical structure. 
Navzkrižne alergenosti z derivati sulfonilsečnine zaradi različne kemične zgradbe ni pričakovati.
• The normal starting dose is 0.5 mg before each main meal. 
- Običajni začetni odmerek je 0,5 mg tik pred vsakim glavnim obrokom.
There are no studies of repaglinide in pregnant women. 
Študije o uporabi repaglinida pri nosečnicah niso bile izvedene.
Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials. 
Uporaba repaglinida v primerih sekundarne odpovedi sekretagogov inzulina v kliničnih preskušanjih ni bila raziskana.
Repaglinide closes ATP-dependent potassium channels in the β-cell membrane via a target protein different from other secretagogues. 
Repaglinid v membrani celic β zapre od ATP-ja odvisne kalijeve kanalčke, in sicer prek tarčne beljakovine, ki pa ni ista kot pri ostalih sekretagogih.
When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control. 
Ob uvedbi ali ukinitvi zdravljenja s temi zdravili je bolnika, ki jemlje repaglinid, treba skrbno nadzirati, da bi odkrili spremembe v urejenosti glikemije.
Patients receiving other oral hypoglycaemic medicinal products Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide. 
Bolniki, ki se zdravijo z drugimi peroralnimi antidiabetiki Bolnike je mogoče na repaglinid prevesti neposredno z drugih peroralnih antidiabetikov.
Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. 
Uporaba repaglinida je indicirana pri odraslih bolnikih s sladkorno boleznijo tipa 2, pri katerih hiperglikemije ni več mogoče zadovoljivo obvladovati z dieto, zmanjšanjem telesne mase in s telesno dejavnostjo.
If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor. 
- Če doživite hipo, zaradi katere se onesvestite, ali doživljate veliko hip, se posvetujte s svojim zdravnikom.
If patients are transferred from another oral hypoglycaemic medicinal product, the recommended starting dose is 1 mg. 
Če bolnik preide na repaglinid z drugega peroralnega antidiabetika, je priporočeni začetni odmerek repaglinida 1 mg.
If you forget to take Enyglid 
Če ste pozabili vzeti zdravilo Enyglid
Enyglid is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). 
Zdravilna učinkovina zdravila Enyglid je repaglinid, ki trebušni slinavki pomaga, da tvori več inzulina in tako znižuje vrednost krvnega sladkorja (glukoze).
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetics of repaglinide has been studied in healthy subjects. 
Vpliv ketokonazola (prototip močnega in kompetitivnega zaviralca CYP3A4) na farmakokinetiko repaglinida so raziskovali pri zdravih prostovoljcih.
Enyglid has been shown to lower the blood sugar, which helps to prevent complications from your diabetes. 
Zdravilo Enyglid dokazano znižuje vrednost krvnega sladkorja, kar pomaga preprečiti razvoj zapletov zaradi sladkorne bolezni.
When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised continue repaglinide treatment. 
Ko simptomi hipoglikemije izzvenijo ali se koncentracija krvnega sladkorja ustali, nadaljujte zdravljenje z repaglinidom.
As insulin sensitivity is increased in diabetic patients with renal impairment, caution is advised when titrating these patients. 
Ker je občutljivost za inzulin pri diabetikih z ledvično okvaro večja, je treba prilagajanje odmerka pri teh bolnikih opraviti še posebej previdno.
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 
Za farmakokinetiko repaglinida je značilen majhen volumen porazdelitve (30 l), kar je v skladu s porazdelitvijo v znotrajcelični tekočini, vezava na plazemske proteine pri človeku pa je obsežna (več kot 98 %)..
Do not take more Enyglid than your doctor has recommended. 
Ne jemljite večjega odmerka zdravila Enyglid, kot vam ga je predpisal zdravnik.
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metabolism of repaglinide. 
Rifampicin, ki je močan induktor tako CYP3A4kot CYP2C8, deluje kot induktor in zaviralec presnove repaglinida.
The following substances may reduce the hypoglycaemic effect of repaglinide: Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics. 
Naslednje učinkovine lahko zmanjšajo hipoglikemični učinek repaglinida: peroralni kontraceptivi, tiazidi, kortikosteroidi, danazol, ščitnični hormoni in simpatikomimetiki.
You can take Enyglid with metformin, another medicine for diabetes, if your doctor prescribes it. 
Zdravilo Enyglid lahko vzamete jemljete skupaj z metforminom, drugim zdravilom za zdravljenje sladkorne bolezni, če vam takšno zdravljenje predpiše zdravnik tako predpiše.
Repaglinide was shown not to be teratogenic in animal studies. 
Študije na živalih so pokazale, da repaglinid ne deluje teratogeno.
not affected by renal disorders (see section 5.2). 
Bolezni ledvic ne vplivajo na repaglinid (glejte poglavje 5.2).
If you get a hypo (low blood sugar) 
V primeru pojava hipe (nizka vrednost krvnega sladkorja)
Such disturbances have only been reported in very few cases after initiation of repaglinide treatment. 
Po uvedbi zdravljenja z repaglinidom so o takšnih motnjah poročali le v zelo redkih primerih.
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketoconazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids. 
Naslednje učinkovine lahko povečajo in/ali podaljšajo hipoglikemični učinek repaglinida: gemfibrozil, klaritromicin, itrakonazol, ketokonazol, trimetoprim, ciklosporin, drugi antidiabetiki, deferasiroks, klopidogrel, zaviralci monoaminooksidaz (zaviralci MAO), neselektivni antagonisti adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (zaviralci ACE), salicilati, nesteroidna protivnetna zdravila, oktreotid, alkohol in anabolni steroidi.
The recommended maximum starting dose of patients transferred to repaglinide is 1 mg given before main meals. 
Priporočeni največji začetni odmerek za bolnike, pri katerih uvajamo repaglinid, je 1 mg pred glavnimi obroki.
Abnormal hepatic function, increased liver enzymes Isolated cases of increased liver enzymes have been reported during treatment with repaglinide. 
Moteno delovanje jeter, zvišana vrednost jetrnih encimov Med zdravljenjem z repaglinidom so poročali o posameznih primerih zvišanja vrednosti jetrnih encimov.
The starting dose of repaglinide is 0.5 mg, taken before main meals; titration is according to blood glucose response as for monotherapy. 
Začetni odmerek repaglinida je 0,5 mg pred glavnimi obroki, prilagajanje odmerka pa poteka glede na odziv glukoze v krvi, tako kot pri monoterapiji.
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. 
Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti in kancerogenega potenciala ne kažejo posebnega tveganja za človeka.
• The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal. 
- Zdravnik lahko odmerek zviša do 4 mg, ki ga vzemite tik pred ali do 30 minut pred glavnimi obroki.
This lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. 
Tako odsotnost farmakodinamičnega učinka so opazili pri odmerkih repaglinida, ki so bili manjši od terapevtskih.
In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. 
Podatki iz raziskav in vitro kažejo, da se repaglinid presnavlja pretežno z encimom CYP2C8, vendar pa tudi s CYP3A4.
Repaglinide can be given in combination with metformin, when the blood glucose is insufficiently controlled with metformin alone. 
Repaglinid se lahko uporablja v kombinaciji z metforminom, če urejenost glikemije samo z metforminom ni zadostna.
Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. 
Klinični podatki, pridobljeni na zdravih prostovoljcih, potrjujejo domnevo, da je CYP2C8 najpomembnejši encim pri presnovi repaglinida in da ima CYP3A4 pri tem le manjšo vlogo, vendar pa se relativen prispevek CYP3A4 v primeru zavrtja CYP2C8 lahko poveča.
Enyglid is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. 
Zdravilo Enyglid uporabljamo za obvladovanje sladkorne bolezni tipa 2 pri odraslih bolnikih kot dodatek k dieti in telesni dejavnosti: zdravljenje je treba uvesti, če samo z dieto, telesno dejavnostjo in zmanjšanjem telesne mase vrednosti sladkorja v krvi ni mogoče nadzirati (ali znižati).
Most cases were mild and transient, and very few patients discontinued treatment due to increased liver enzymes. 
Zvišanje je bilo večinoma blago in prehodno, zaradi njega pa je bilo treba zdravljenje prekiniti pri zelo majhnem številu bolnikov.
Your blood sugar may get too high (hyperglycaemia). 
Krvni sladkor v krvi se vam lahko tudi preveč zviša (to imenujemo hiperglikemija).
Combination with insulin secretagogues 
Kombinacija s sekretagogi inzulina
Enyglid can also be given with metformin, another medicine for diabetes. 
Zdravilo Enyglid se lahko jemlje skupaj z metforminom, drugim zdravilom za zdravljenje sladkorne bolezni.
It cannot be excluded that other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John's wort, may have a similar effect. 
Podobnega učinka drugih induktorjev, kot so fenitoin, karbamazepin, fenobarbital in šentjanževka, ni mogoče izključiti.
Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone. 
Uporaba repaglinida je indicirana tudi v kombinaciji z metforminom pri odraslih bolnikih s sladkorno boleznijo tipa 2, pri katerih glikemija samo z metforminom ni zadovoljivo urejena.
Dosage adjustment of these compounds when co-administered with repaglinide is therefore not necessary. 
Prilagoditev odmerka teh zdravil pri sočasni uporabi ni potrebna.
Each tablet contains 0.5 mg, 1 mg, 2 mg repaglinide. 
Ena tableta vsebuje 0,5 mg, 1 mg, 2 mg repaglinida.
If you stop taking Enyglid 
Če ste prenehali jemati zdravilo Enyglid
Intraindividual variability is low to moderate (35%) and as repaglinide should be titrated against the clinical response, efficacy is not affected by interindividual variability. 
Variabilnost pri posameznem bolniku je majhna do zmerna (35 %), odmerek repaglinida pa je treba titrirati do dosege kliničnega odziva.
The recommended maximum single dose is 4 mg taken with main meals. 
Priporočeni največji posamični odmerek repaglinida je 4 mg ob glavnih obrokih.
Seven days pre-treatment with rifampicin (600 mg), followed by coadministration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition). 
Pri sedemdnevnem predzdravljenju z rifampicinom (v odmerku 600 mg) in kasnejšemu dodatku repaglinida (v enkratnem odmerku 4 mg) sedmi dan, se je vrednost AUC znižala za 50 % (kombinirani učinek indukcije in inhibicije).
Cardiovascular disease 
Srčne bolezni kardiovaskularna bolezen redki
What you need to know before you take Enyglid 
Kaj morate vedeti, preden boste vzeli zdravilo Enyglid
Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided. 
Ker profil varnosti te kombinacije zdravil pri odmerkih, višjih od 0,25 mg za repaglinid in 320 mg za trimetoprim še ni bil ugotovoljen, se je treba sočasni uporabi trimetoprima in repaglinida izogibati.
Repaglinide is rapidly absorbed from the gastrointestinal tract, which leads to a rapid increase in the plasma concentration of the active substance. 
Repaglinid se hitro absorbira iz prebavil, zato se njegova koncentracija zdravilne učinkovine v plazmi hitro zveča.
Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or warfarin at steady state, when administered to healthy volunteers. 
Repaglinid pri zdravih prostovoljcih ni imel klinično pomembnega vpliva na farmakokinetične lastnosti digoksina, teofilina ali varfarina v stanju dinamičnega ravnovesja.
Glycosylated haemoglobin levels are also of value in monitoring the patient's response to therapy. 
Za spremljanje bolnikovega odziva na zdravljenje je pomembna tudi koncentracija glikoziliranega hemoglobina.
However, no exact dosage relationship exists between repaglinide and the other oral hypoglycaemic medicinal products. 
Vendar pa med odmerjanjem repaglinida in drugih peroralnih antidiabetikov ni natančnega razmerja.
In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful dose titration is required to avoid hypoglycaemic reactions. 
Pri oslabelih in podhranjenih bolnikih mora biti začetno in vzdrževalno odmerjanje konzervativno.
Embryotoxicity, abnormal limb development in rat foetuses and new born pups, was observed in female rats exposed to high doses in the last stage of pregnancy and during the lactation period. 
Pri zarodkih in mladičih podgan, katerih matere so bile v zadnjem obdobju brejosti in med laktacijo izpostavljene visokim odmerkom repaglinida, so opazili embriotoksične učinke in nenormalen razvoj okončin.
Hypersensitivity reactions of the skin may occur as erythema, itching, rashes and urticaria. 
Preobčutljivostne kožne reakcije se lahko pojavijo kot rdečina, srbenje, izpuščaj ali urtikarija.
Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal. 
Bolniku morate naročiti, naj v primeru, če izpusti (ali zaužije dodatni) obrok, izpusti (ali vzame dodatni)
- Severe hepatic function disorder. 
- Hudo moteno delovanje jeter.
In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage. 
Za določitev odmerka v primeru sočasne uporabe z drugimi zdravilnimi učinkovinami glejte poglavji 4.4 in 4.5.
If your blood sugar gets too high 
V primeru prekomernega zvišanja vrednosti krvnega sladkorja
• The other ingredients are: microcrystalline cellulose (E460); calcium hydrogen phosphate, anhydrous; croscarmellose sodium; povidone K25; glycerol; magnesium stearate; meglumine; poloxamer; yellow iron oxide (E172) only in the 1 mg tablets and red iron oxide (E172) only in the 2 mg tablets 
- Druge sestavine zdravila so mikrokristalna celuloza (E460), brezvodni kalcijev hidrogenfosfat, premreženi natrijev karmelozat, povidon K 25, glicerol, magnezijev stearat, meglumin, polokasmer, rumeni železov oksid (E172) - samo v 1-mg tabletah in rdeči železov oksid (E172) - samo v 2-mg tabletah.
The AUC (SD) after 2 mg single dose exposure (4 mg in patients with hepatic insufficiency) was 31.4 ng/ml x hr (28.3) in healthy volunteers, 304.9 ng/ml x hr (228.0) in patients with hepatic insufficiency, and 117.9 ng/ml x hr (83.8) in the elderly type 2 diabetic patients. 
Po posamičnem odmerku 2-mg (4-mg pri bolnikih z insuficienco jeter) je vrednost AUC (SD) pri zdravih prostovoljcih znašala 31,4 ng/ml/h (28,3), pri bolnikih z insuficienco jeter 304,9 ng/ml/h (228), pri starostnikih s sladkorno boleznijo tipa 2 pa 117,9 ng/ml/h (83,8).